Press Releases

GlobeNewswire, Inc.

Key Q1 2026 Highlights Revenue: $723M, down 3.7%. Growth in Government and Transportation segments Pre-tax Income (Loss): $(27)M, improved by $29M year-over-year Adj. EBITDA(1): $49M, improved by $12M year-over-year Adj. EBITDA Margin(1): 6.8%,...

GlobeNewswire, Inc.

First Quarter 2026 and Selected Highlights: VEVYE® delivered record new and total prescription performance (despite an approximate 18% decline in the overall branded dry eye category) VEVYE demand growth on track to deliver 2026 revenue of over...

GlobeNewswire, Inc.

Sewickley, PA , May 11, 2026 (GLOBE NEWSWIRE) -- The Kelley Financial Group gains national recognition as Micah Kelley earns placement on the Forbes Best-in-State Wealth Advisors 2026 list.

GlobeNewswire, Inc.

Q1 Revenue of $30.2 Million; Net Loss of $4.0 Million, an Improvement of $5.1 Million; and Adjusted EBITDA of $5.0 Million, or $5.8 Million Excluding Litigation Expenses LOS ANGELES, May 11, 2026 (GLOBE NEWSWIRE) -- Playboy, Inc. (NASDAQ: PLBY)...

GlobeNewswire, Inc.

– LOQTORZI® net revenue of $11.8 million in Q1 2026 – – Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, timing for data readouts tracking to projections – – Tagmokitug, CCR8 Treg depleter...

GlobeNewswire, Inc.

CHANDLER, Ariz., May 11, 2026 (GLOBE NEWSWIRE) -- VirTra, Inc. (Nasdaq: VTSI) (“VirTra” or the “Company”), a global provider of judgmental use-of-force and firearms training simulators, reported results for the first quarter ended March 31, 2026....

GlobeNewswire, Inc.

Delivered Revenue Within Guidance Range and Adjusted EBITDA Well Above the High-End of Guidance Range First Quarter Revenue Decline of 1.5% Year-Over-Year; Revenue Growth on a Constant Currency Basis of 0.2% Net Loss of $8.8 million; Adjusted...

GlobeNewswire, Inc.

On track for regulatory submission of MGX-001 to advance global clinical program, including investigational new drug application (“IND”) in 4Q 2026 Publication in Nature Structural & Molecular Biology highlights potential of MG119-28, a...

GlobeNewswire, Inc.

In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”), the event-driven primary disease-free survival (“DFS”) analysis is anticipated mid-year 2026 The Company raised net proceeds...

GlobeNewswire, Inc.

Completed transformative acquisition of PXL-770, (now SCY-770), an innovative, highly selective, direct AMPK activator for the treatment of autosomal dominant polycystic kidney disease (ADPKD) A Phase 2 proof-of-concept study of SCY-770 in ADPKD...

GlobeNewswire, Inc.

NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Allied Gaming & Entertainment Inc. (NASDAQ: AGAE) (the “Company”) today announced that its Board of Directors has approved a proposal to be submitted to a special meeting of stockholders (the “Special...

GlobeNewswire, Inc.

Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted agents ERAS-0015 monotherapy expansion and...

GlobeNewswire, Inc.

Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) Pivotal Phase 2 first interim analysis expected in Q4 2026 BLA submission anticipated in 2028 Phase 1 with eti-cel in r/r NHL (NATHALI-01 trial) Full Phase 1 dataset expected in Q4 2026...

GlobeNewswire, Inc.

Full year fiscal 2026 revenue from continuing operations increased 9%; constant currency organic revenue growth was 7% Full year fiscal 2026 as reported diluted EPS from continuing operations increased to $7.93; adjusted EPS per diluted share...

GlobeNewswire, Inc.

Delivered Q1 2026 Total Revenues of $149.4 Million Results include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® Reported Cash and Cash Equivalents of $755.9 Million and No Funded Debt as of March 31, 2026 CORAL GABLES, Fla.,...

GlobeNewswire, Inc.

Pipeline Advancing as Planned, Leading with OCS-01 Key Milestone Completion of LPLV in Both DIAMOND Phase 3 Trials; Data Readout on Track for June 2026 Licaminlimab PREDICT-1 Trial in Active Site Recruitment Phase, Pioneering a Genotype-Driven...

GlobeNewswire, Inc.

CUPERTINO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Ambow Education Holding Ltd. (“Ambow” or the “Company”) (NYSE American: AMBO) a U.S.-based innovator of AI-powered phygital (physical + digital) solutions for education, corporate collaboration...

GlobeNewswire, Inc.

In the first full quarter since launch, 2,145 healthcare providers prescribed TONMYA®, 3,588 patients initiated treatment, and ~5,400 prescriptions were filled Agreement signed in May with leading group purchasing organization (GPO) that provides...

GlobeNewswire, Inc.

Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026 Phase 1 Clinical Trial Initiated for SEP-479, Oral Small Molecule PTH1R...

GlobeNewswire, Inc.

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is progressing well with the interim analysis anticipated in 4Q 2026 Positive...